Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corporation has released its third-quarter fiscal 2026 results, reporting sales of US$311.42 million and net income of US$51.05 million, alongside higher basic and diluted earnings per ...

"We expect organic growth in the fourth quarter to be approximately flat" and added that "excluding the impact of the cell therapy headwinds, we anticipate low single-digit underlying growth across ...

Bio-Techne Corporation ( TECH) Q3 2026 Earnings Call May 6, 2026 9:00 AM EDT Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter and Fiscal Year 2026. [Operator ...

Life sciences company Bio-Techne (NASDAQ:TECH) fell short of the market’s revenue expectations in Q1 CY2026, with sales ...

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026. Third ...

Bio-Techne Corporation today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively ...

Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be ...

Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.

Bio-Techne To Present At The Bank Of America Securities 2026 Global Healthcare Conference. MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Kim ...